Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. Chief Commercial Officer Neera Clase received 10,587 stock options to buy common shares and 6,678 restricted stock units on November 3, 2026. The options have a $72.64 per-share exercise price and expire November 2, 2036. Twenty-five percent of the option shares vest on November 1, 2027, with 1/48th vesting monthly thereafter for three years. The RSUs vest in four equal annual installments on December 15 of 2027, 2028, 2029 and 2030. Both awards are subject to continuous service. Her reported direct positions following the awards were 10,587 options and 6,678 RSUs.
Tarsus Pharmaceuticals, Inc. (TARS) Chief Commercial Officer Neera Clase reported direct ownership of 14,800 common shares as of November 1, 2026. She also reported six stock-option positions covering 23,000, 18,701, 14,909, 9,119, 6,126 and 5,007 underlying shares, at respective exercise prices of $25.56, $19.59, $15.00, $35.50, $44.54 and $74.90. Four restricted stock unit awards cover 2,864, 3,080, 3,014 and 3,147 shares, with vesting schedules beginning March 15, 2027, subject to continuous service.
Tarsus Pharmaceuticals, Inc. (TARS) reported that FMR LLC and Abigail P. Johnson each beneficially owned 3,143,158 shares, representing 6.4% of the common stock. FMR LLC reported sole voting power over 3,139,690 shares and sole dispositive power over 3,143,158 shares. Abigail P. Johnson reported no voting power and sole dispositive power over 3,143,158 shares.
Tarsus Pharmaceuticals, Inc. (TARS) reported third-quarter 2026 product sales of $194.6 million, compared with $118.7 million a year earlier. Sales came from XDEMVY, and total revenue was $194.6 million. Net loss was $668.3 million, including $632.2 million of acquired in-process research and development expense; total operating expenses were $856.7 million.
For the nine months ended September 30, 2026, Tarsus generated $30.6 million in operating cash, versus $31.8 million used in the 2025 period. At September 30, cash and cash equivalents were $136.5 million and marketable securities were $173.1 million. The company acquired iRenix in July and Alkeus in September, issuing 607,093 shares to iRenix securityholders and 2,908,692 shares for Alkeus. An August private placement generated approximately $120.1 million in net proceeds. Management estimated existing capital resources would cover projected operating expenses and other liquidity needs for at least 12 months from the statements’ issuance date.
Tarsus Pharmaceuticals, Inc. (TARS) reported third-quarter 2026 net product sales of $194.6 million, an approximately 64% increase from the same period in 2025. More than one million XDEMVY bottles had been dispensed, and cumulative net product sales since launch had surpassed $1 billion.
Third-quarter net loss was $668.3 million, compared with $12.6 million a year earlier. The quarter included $632.2 million of acquired in-process research and development expense related to the completed iRenix Medical and Alkeus acquisitions; the acquired programs were expensed because they had no alternative future use. Research and development expenses were $44.2 million and selling, general and administrative expenses were $168.0 million.
As of September 30, 2026, cash, cash equivalents and marketable securities totaled $309.6 million. Net product sales for the first nine months were $513.9 million, compared with $299.7 million in 2025. The average number of eye care professionals prescribing XDEMVY at least daily increased approximately 20% from the beginning to the end of the third quarter.
Tarsus Pharmaceuticals, Inc. (TARS) registers up to 2,908,692 shares of common stock for resale by selling stockholders. The shares were issued as consideration for Tarsus’s acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, and Tarsus will receive no proceeds from the resales. The holders may sell from time to time after the registration statement becomes effective, in public or private transactions, at fixed, market-related, varying or negotiated prices. The selling-stockholder table includes, among others, BCLS Fund III Investments, LP with 917,570 shares and Forbion Growth Opportunities Fund III Coöperatief U.A. with 64,087 shares.
Approximately 2,630,416 shares are subject to a two-month lock-up following the acquisition closing, subject to customary exceptions; approximately 1,994,414 shares are subject to volume limitations tied to average trading volume for three months after the lock-up period. Approximately 278,276 shares are subject to neither restriction.
Tarsus Pharmaceuticals, Inc. registered for resale by selling stockholders up to 2,232,144 shares of common stock, comprising 2,098,519 shares of common stock and 133,625 shares issuable upon exercise of pre-funded warrants. The securities were issued in a private placement under an August 5, 2026 purchase agreement. Sales may occur from time to time after effectiveness. Selling stockholders receive resale proceeds; Tarsus receives none from resales but may receive nominal proceeds if holders exercise warrants for cash.
Warrant exercise is prohibited if it would put a holder above its elected 4.99% beneficial-ownership limit. Tarsus, its executive officers and directors, and certain other stockholders agreed, subject to exceptions, not to dispose of or hedge common stock or securities convertible into or exchangeable for common stock from the Purchase Agreement date through the date 90 days after it. Alkeus Pharmaceuticals, Inc.’s audited historical financial statements incorporated by reference include an auditor’s explanatory paragraph about its ability to continue as a going concern. Tarsus had 49,303,413 shares outstanding as of September 25, 2026; its common stock’s last reported sale price was $74.40 on October 12, 2026.
Tarsus Pharmaceuticals (TARS) amended its acquisition-related report to add Alkeus Pharmaceuticals’ audited and interim financial statements and unaudited pro forma information. Tarsus said the acquisition of Alkeus had been completed; the pro forma information is informational and does not represent actual combined results or project future results.
Alkeus reported a fiscal 2025 net loss of $49.8 million, compared with $18.5 million in fiscal 2024, and net cash used in operating activities of $48.2 million versus $18.9 million. For the nine months ended June 30, 2026, Alkeus recorded a $35.3 million net loss versus $37.5 million in the prior-year period; cash and cash equivalents were $48.7 million at June 30, 2026.
Alkeus reported a $109.6 million accumulated deficit and said its need for additional capital to fund operations for at least 12 months from September 3, 2026 raises substantial doubt about its ability to continue as a going concern. It plans to seek funding through equity or debt financing and other capital sources, without assurance those plans will succeed.
Tarsus Pharmaceuticals, Inc. (TARS) director David E. I. Pyott reported the settlement and exercise of 201 Restricted Stock Units, each converting into one share of common stock, on September 15, 2026. The 201 resulting shares are held indirectly through the David E. I. Pyott Trust, which now holds 9,575 common shares. Following the transaction, Pyott also holds 605 RSUs, which vest in equal installments on September 15, 2026, December 15, 2026, March 15, 2027 and June 15, 2027, subject to continuous service as a non-employee director. The filing states that 1,383 of the trust’s shares were previously held directly and transferred to the trust with no change in Pyott’s pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Tarsus Pharmaceuticals, Inc. (TARS) reported that director Wendy L. Yarno exercised 302 Restricted Stock Units (RSUs) on September 15, 2026, settling them into 302 shares of common stock. The RSU award was granted for service as a non-employee director, and no Rule 10b5-1 trading plan is indicated.
After this exercise, Yarno holds 16,956 shares of common stock directly and 907 RSUs directly. Each RSU represents a contingent right to receive one share of Tarsus common stock, vesting in equal installments through June 15, 2027, subject to continuous board service.